@Akki
You crack me up
i thought it was all about the secondary results for you, now all of a sudden you try to cast doubt on safety and tolerability
yet you fail to mention
In regard to the trial’s secondary endpoints that assess drug activity/efficacy, the Company is highly encouraged that the data to date is indicative of drug effect, particularly considering the small number of patients evaluated and that the progress of the final three patients (due to complete dosing in November) appears consistent with this view that the drug is showing activity. Early indications of an immunomodulatory effect are underpinned via observations that certain immune cell numbers (in particular those expressing the CD49d, the biological target of ATL1102) are trending downward during the treatment phase while returning to around starting levels post dosing. As an indicator of ATL1102’s suggestive positive effects on disease progression (being the type of endpoints required for future product registration) in the current trial, ANP has previously referenced the Ricotti et al 2016 publication that evaluated disease progression in non-ambulant boys over a 6 month period, where a significant mean reduction in upper body muscle strength of the subjects was observed. By comparison, the data on the first 6 patients completing dosing in the ATL1102 trial, shows a distinct improvement in these strength parameters over the losses noted in the Ricotti publication (refer Appendix A).
Note the Highlighted Points Akki
drug is showing activity
CD49d, the biological target of ATL1102) are trending
positive effects on disease progression
ATL1102 trial, shows a distinct improvement in these strength parameters
Is there any wonder we are seeing todays price action and this is at the low dose of 25mg which was nothing compared to the dosing of 600mg for the first two weeks in the Ms trials reducing to 400mg thereafter
So just to highlight ANPs Potential here
WHAT DO WE HAVE
ATL1103 successful completion of a Ph2 trial with proven results
Atl1102 successful Ph2 In rrms with proven results
We now have what appears to be a successful Ph2 in DMD
And lets not forget here the results from this trial will be put forwards to the FDA in an effort to increase the dosing and start a Ph2b in the SPMS field another untaped market place
I am still calling 25c the bottom of the ladder
see how we go
Chart, page-599
-
- There are more pages in this discussion • 5,307 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.9¢ |
Change
-0.003(4.17%) |
Mkt cap ! $62.20M |
Open | High | Low | Value | Volume |
7.2¢ | 7.3¢ | 6.9¢ | $100.8K | 1.426M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 444999 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 135024 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 444999 | 0.069 |
1 | 685 | 0.068 |
1 | 15060 | 0.066 |
3 | 516040 | 0.065 |
1 | 219429 | 0.064 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 135024 | 1 |
0.073 | 67500 | 1 |
0.075 | 100000 | 1 |
0.076 | 143169 | 1 |
0.077 | 117090 | 2 |
Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
Last
7.0¢ |
  |
Change
-0.003 ( 1.41 %) |
|||
Open | High | Low | Volume | ||
7.2¢ | 7.3¢ | 7.0¢ | 150480 | ||
Last updated 15.59pm 30/04/2024 ? |
Featured News
PER (ASX) Chart |